# Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

> **NCT03524820** · PHASE2 · TERMINATED · sponsor: **Hadassah Medical Organization** · enrollment: 3 (actual)

## Conditions studied

- Cancer of Colon

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT03524820
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-17
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** By Merck
- **Last updated:** 2022-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03524820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03524820, "Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03524820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*